Albert Labs International Past Earnings Performance
Past criteria checks 0/6
Albert Labs International has been growing earnings at an average annual rate of 64.8%, while the Biotechs industry saw earnings growing at 13.4% annually.
Key information
64.8%
Earnings growth rate
69.8%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | n/a |
| Return on equity | n/a |
| Net Margin | n/a |
| Last Earnings Update | 30 Sep 2023 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How Albert Labs International makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 23 | 0 | -2 | 1 | 1 |
| 30 Jun 23 | 0 | -3 | 2 | 1 |
| 31 Mar 23 | 0 | -4 | 2 | 1 |
| 31 Dec 22 | 0 | -7 | 3 | 2 |
| 30 Sep 22 | 0 | -7 | 3 | 1 |
| 30 Jun 22 | 0 | -6 | 2 | 1 |
| 31 Mar 22 | 0 | -6 | 2 | 1 |
| 31 Dec 21 | 0 | -2 | 1 | 0 |
Quality Earnings: VB50 is currently unprofitable.
Growing Profit Margin: VB50 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if VB50's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare VB50's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: VB50 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-13.8%).
Return on Equity
High ROE: VB50's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.